Announcement : Medochemie Limited to manufacture selected products for Liquim’s export market

Liquim Limited is pleased to announce the appointment of Medochemie Limited to manufacture selected products for Liquim’s export market.

Medochemie was established by Dr. Andreas Pittas (current Chairman and CEO) in 1976 with headquarters in Limassol, Cyprus.  It specialises in pharmaceuticals and over-the-counter medicines and now ranks among the top 200 generic pharmaceutical companies in the world.

Medochemie has 22 core offices worldwide.  It operates in 107 countries and owns 13 manufacturing plants and facilities, of which nine are in Cyprus, one in the Netherlands, and three in Vietnam.  The company employs over 1800 people.

Liquim has selected Medochemie as a strategic manufacturing partner for many reasons:


  • Medochemie is still driven by Dr Pittas’ philosophy “To provide every human being around the globe with quality and affordable drug treatment in a manner that supports sustainability”.  This aligns well with Liquim’s mission to be leaders in the medical and biotech space, offering plant-based, cost-effective, innovative solutions to achieve better health outcomes and a higher quality of life for everyone.
  • Medochemie has thirteen state-of-the-art manufacturing facilities across Europe and Asia. Each is designed following the latest technology and fully complies with the current regulations for Good Manufacturing Practices (cGMPs) of the European Union and the World Health Organization (WHO).
  • Medochemie’s facilities are equipped to produce nasal, oral, parenteral, and topical presentations, including penicillins, cephalosporins, dry powder inhalers and liquid solutions
  • Medochemie will manufacture Liquim’s Nasal Spray. Medochemie has the capacity to meet our sales forecasts and to increase the volumes as the need arises.  Furthermore, it can produce Liquim’s range of Oral products too.

All Liquim products are alcohol (ethanol)-free and contain plant-derived ingredients which are on the TGA lists of ingredients deemed safe for human consumption.

“I am thrilled that Liquim has reached this significant milestone in its commercialisation journey.  With product scheduled to ship by Q3 2023, we are well on the way to achieving our mission of delivering affordable plant-derived solutions to provide better health outcomes to the wider global community”, Sheryl Frame, CEO, Liquim Ltd.

Note: The product is not yet available for sale in Australia.


This website is designed to serve individuals interested in gathering information regarding Liquim Limited for investment or business purposes. The website includes details about products that may have varying availability or trademarks in different countries or for different purposes. If you are looking for information about Liquim products, we recommend you visit the dedicated product website in your country of residence. It's important to note that nothing presented on this website should be construed as solicitation, promotional material, or advertising for any product, including those in development. Furthermore, the information provided on this website is not intended to offer medical advice, and it should not be used as a substitute for guidance from a qualified healthcare professional or physician.